Pre-clinical evaluation of a novel anti-tumor agent in hematological malignancies

• Forschungsstelle: INNOSUISSE
• Projektnummer: 8368.2;8 LSPP-LS
• Projekttitel Englisch: Pre-clinical evaluation of a novel anti-tumor agent in hematological malignancies

Kurzbeschreibung (Englisch)

Pre-clinical evaluation of a novel anti-tumor agent in hematological malignancies

Kurzbeschreibung (Französisch)

Pre-clinical evaluation of a novel anti-tumor agent in hematological malignancies

Abstract (Französisch)

APO866 is a novel drug inhibiting NAD metabolism and inducing cell death. APO866 has a definite potential for treatment of blood cancers but not all cancers respond to APO866. Therefore, there is a need to personalize medical treatment with APO866. The aims of the project are to define blood cancer indications and markers associated with APO866 sensitivity, and highlight drug combinations optimizing APO866 efficacy.Overall, the project would validate APO866 as a novel agent for treatment of blood cancers in patients, and is essential for its inclusion into relevant clinical trials.